Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 5
2020 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation.
Williams DS, Mouradov D, Newman MR, Amini E, Nickless DK, Fang CG, Palmieri M, Sakthianandeswaren A, Li S, Ward RL, Hawkins NJ, Skinner I, Jones I, Gibbs P, Sieber OM. Williams DS, et al. Mod Pathol. 2020 Jul;33(7):1420-1432. doi: 10.1038/s41379-020-0496-1. Epub 2020 Feb 11. Mod Pathol. 2020. PMID: 32047231 Free article.
Circulating biomarkers in patients with glioblastoma.
Müller Bark J, Kulasinghe A, Chua B, Day BW, Punyadeera C. Müller Bark J, et al. Br J Cancer. 2020 Feb;122(3):295-305. doi: 10.1038/s41416-019-0603-6. Epub 2019 Oct 31. Br J Cancer. 2020. PMID: 31666668 Free PMC article. Review.
U.K. utility weights for the EORTC QLU-C10D.
Norman R, Mercieca-Bebber R, Rowen D, Brazier JE, Cella D, Pickard AS, Street DJ, Viney R, Revicki D, King MT; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group and the MAUCa Consortium. Norman R, et al. Health Econ. 2019 Dec;28(12):1385-1401. doi: 10.1002/hec.3950. Epub 2019 Sep 3. Health Econ. 2019. PMID: 31482619
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.